Immusoft cleared to advance ISP-001 into clinic for MPS I
Sep. 2, 2022
The FDA has cleared Immusoft Corp.'s IND for ISP-001 (iduronicrin genleukocel-T) for the treatment of mucopolysaccharidosis type I (MPS I), allowing initiation of a phase I trial.
